Lantheus Holdings, Inc. (LNTH): Revenue
$1.54B
Year ended 2025-12-31
$1.56B
Trailing 12 months to 2026-06-30
+18.1%
3-year compound annual growth
+35.3%
5-year compound annual growth
+18.0%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.54B | +0.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $1.53B | +18.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.30B | +38.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $935.06M | +119.9% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $425.21M | +25.3% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $339.41M | -2.3% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $347.34M | +1.2% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $343.37M | +3.6% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $331.38M | +9.8% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $301.85M | +2.9% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $293.46M | -2.7% | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $301.60M | +6.3% | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | $283.67M | n/a | 2016-03-02, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $1.54B | +0.5% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $2.73B | -1.9% |
| Neogen Corp (NEOG) | 2026-05-31 | $870.40M | -2.7% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $824.50M | -1.6% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $4.30B | +10.4% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $67.67M | +16.9% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $40.52M | +7.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $27.64M | +4.3% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $9.22M | +0.4% |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗